

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/996,357 11/27/2001		Malcolm L. Gefter	PPI-105	1918	
959	7590 01/14/2004		EXAMINER		
LAHIVE & 28 STATE S	COCKFIELD, LLP.	NICHOLS, CHRISTOPHER J			
BOSTON, I		ART UNIT	PAPER NUMBER		
,		1647			
			D. 1		

Please find below and/or attached an Office communication concerning this application or proceeding.

3

		Applica	ation No.	Applicant(s)				
		09/996	3,357	GEFTER ET AL.				
	Office Action Summary	Exami	ner	Art Unit				
			pher Nichols, Ph.D.	1647				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
	Responsive to communication(s) fil	ed on <u>25 July 2003</u>	•					
• • • • • • • • • • • • • • • • • • • •		2b)⊠ This action is						
,								
Dispositi	on of Claims							
5) 6) 7)	Claim(s) 1-78 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) is/are subject to restriction and/or election requirement.							
Application Papers								
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. §§ 119 and 120								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.								
2) Notice	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review rmation Disclosure Statement(s) (PTO-1449)		4) Interview Summary 5) Notice of Informal I					
3)	mation Disclosure Statement(s) (F 10-1448)	. apor 110(0)	o, <u> </u>					

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-22, drawn to a *compound* comprising the formula I-L-P and pharmaceutical compositions thereof, classified in class 424, subclass 130.1, for example.
 - Claims 23-26, drawn to a method for treating a subject suffering from an amyloidogenic disorder, classification dependent upon compound structure used.
 - III. Claims 27-52, drawn to a method of producing a polypeptide, nucleic acids, vectors, and recombinant cells comprising same, classified in class 435, subclass 325, for example.
 - IV. Claims 53-73, drawn to a *polypeptide* comprising an immunoglobulin heavy chain constant region, or fragment thereof, that retains the ability to bind an Fc receptor and an amino acid sequence capable of binding to an amyloidogenic protein, classified in class 530, subclass 387.1, for example.
 - V. Claims 74-76, drawn to a method of preparing a therapeutic agent, classification dependent upon agent structure.
 - VI. Claims 77-78, drawn to a *therapeutic agent*, classification dependent upon agent structure.
- 2. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1647

- 3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions II, III, and V are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention II requires search and consideration of treating an amyloidogenic disorder, which is not required by any of the other Inventions. Invention III requires search and consideration of producing a polypeptide, which is not required by any of the other Inventions. Invention V requires search and consideration of preparing a therapeutic agent, which is not required by any of the other Inventions.
- 4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions I, IV, and VI are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The *compound* of Invention I can be prepared by processes which are materially different from polypeptide of Invention IV and the therapeutic agent of Invention VI such as by chemical synthesis, or by isolation and purification from natural sources. The *polypeptide* of Invention IV can be prepared by processes which are materially different from compound of Invention I and the therapeutic agent of Invention VI such as by chemical synthesis, or by isolation and purification from natural sources. The *therapeutic agent* of Invention VI can be prepared by processes which are materially different from compound of Invention VI can be prepared by processes which are materially different from compound of Invention I and the

Page 3

Art Unit: 1647

polypeptide of Invention IV such as by chemical synthesis, or by isolation and purification from natural sources.

- 5. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the *compound* of Invention I can be used in materially different methods such as diagnostic or biochemical (to identify binding partners).
- 6. Inventions III and IV are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the *polypeptide* of Invention III can be made through materially different methods such as by chemical synthesis or isolation from natural sources.
- 7. Inventions V and VI are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the therapeutic agent of Invention VI can be made through materially different methods such as by chemical synthesis or isolation from natural sources.
- 8. Inventions I and each of III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of

Art Unit: 1647

operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions I and each of III and V are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions III and V do not recite the use or production of the *compound* of Invention I.

- 9. Inventions IV and each of II and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions IV and each of II and V are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions II and V do not recite the use or production of the *polypeptide* of Invention IV.
- 10. Inventions VI and each of II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions VI and each of II and III are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions VI do not recite the use or production of the *therapeutic agent* of Invention VI.
- 11. The Examiner has required restriction between product and method claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn method claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Method claims that depend** from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Art Unit: 1647

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

- 12. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined method claims will be withdrawn, and the rejoined method claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and method claims may be maintained. Withdrawn method claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the method claims should be amended during prosecution either to maintain dependency on the method claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**
- 13. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the Examiner before the patent issues. See MPEP § 804.01.
- 14. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1647

15. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

16. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Page 7

Page 8

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Christopher James Nichols**, **Ph.D.** whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:00AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Gary Kunz, Ph.D.** can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN

January 12, 2004

GARY KUNZ

SUPERVISORY PATENT EXAMINER